FDA's Jan Welch Is ORA's First Device Director; New Acting CDRH Compliance Chief Named
This article was originally published in The Gray Sheet
Executive Summary
FDA's Jan Welch has vacated the role of acting director of CDRH's Office of Compliance, moving to a newly created position in the agency's Office of Regulatory Affairs aimed at coordinating medical device facility inspections and other related activities. Sean Boyd, previously deputy director of the Division of Radiological Health in CDRH's Office of In Vitro Diagnostics and Radiological Health, is the new acting head of the CDRH Compliance Office.
You may also be interested in...
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.
Lilly, BMS, Microsoft On GenAI’s Machine-First Approach Success, Cell Therapy Use, Regulation
As Eli Lilly chief information and digital officer Rau speaks of generative AI models training humans on drug discovery, Bristol Myers Squibb CDTO Meyers of wearables aiding cell therapy and Microsoft Research India MD Rajamani of interoperability no longer being a huge challenge, a discussion at the BioAsia summit highlights a fundamental shift in R&D approaches.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.